According to the asset manager, plan sponsors should focus on investments, plan management and governance to help plans achieve and maintain full funding.
Terminating the $1.3 billion plan is significant because the pharmaceutical industry is one of the few strongholds for DB plans, according to a Willis Towers Watson report.